AURO-RAMIPRIL TABLETS 1.25 ramipril 1.25mg tablet bottle

Land: Ástralía

Tungumál: enska

Heimild: Department of Health (Therapeutic Goods Administration)

Kauptu það núna

Download Opinber matsskýrsla (PAR)
29-11-2017

Virkt innihaldsefni:

ramipril, Quantity: 1.25 mg

Fáanlegur frá:

Arrotex Pharmaceuticals Pty Ltd

INN (Alþjóðlegt nafn):

Ramipril

Lyfjaform:

Tablet, uncoated

Samsetning:

Excipient Ingredients: pregelatinised maize starch; sodium bicarbonate; lactose monohydrate; sodium stearylfumarate; croscarmellose sodium

Stjórnsýsluleið:

Oral

Einingar í pakka:

30

Gerð lyfseðils:

(S4) Prescription Only Medicine

Ábendingar:

? Treatment of hypertension. Data are currently not available to support the use of Ramipril in renovascular hypertension. ,? Post MI heart failure ,? Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? For reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? For reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmHg or diastolic blood pressure >90mmHg (or on antihypertensive treatment); total cholesterol >5.2mmol/L; HDL cholesterol <0.9mmol/L; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Vörulýsing:

Visual Identification: White to off-white coloured, flat faced bevel edged round uncoated tablet debossed with 'H' &'17' on one side and plain on other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Leyfisstaða:

Licence status A

Leyfisdagur:

2011-10-06